ADDF STATEMENT ON LECANEMAB DATA PRESENTED AT CTAD

Positive results from new amyloid-clearing drug represent starting point for Alzheimer's treatment, while combination therapy remains holy grail SAN FRANCISCO, Nov. 29, 2022 /PRNewswire/ -- Based on study results presented today at the 15th Clinical Trials on Alzheimer's Disease (CTAD)...